Compared to STAG2-wild-type AML, in-frame mutations of CEBPA-bZIP (5.7% vs. 9.1%, p = 0.004) as well as mutated NPM1 (14.8% vs. 32.0%, p < 0.001) and FLT3-ITD (9.1% vs. 22.3%, p = 0.002) were significantly less common (Fig. 1B, Table S5). This evidence concerns the gene STAG2 and acute myeloid leukemia.